October 13, 2023

FibroGen announces discontinuation of LELANTOS-2 Open Label Extension

PPMD has recently learned that FibroGen has discontinued the LELANTOS-2 Open Label Extension. This news follows the August 2023 release of negative topline results of the Phase 3 LELANTOS-2 trial of pamrevlumab, FibroGen’s investigational anti-fibrotic…

Learn More

August 30, 2023

FibroGen Announces Topline Data from Phase 3 LELANTOS-2 Study

FibroGen has announced topline results of the Phase 3 LELANTOS-2 trial of pamrevlumab, their investigational anti-fibrotic monoclonal antibody, for ambulatory patients with Duchenne muscular dystrophy.  Although generally safe and well tolerated, pamrevlumab did not meet…

Learn More

June 7, 2023

FibroGen Announces Topline Data from Phase 3 LELANTOS-1 Study

This morning, FibroGen announced topline data from the Phase 3 LELANTOS-1 study of pamrevlumab, their investigational monoclonal antibody, for non-ambulatory patients with Duchenne muscular dystrophy.   Although generally safe and well tolerated, pamrevlumab did not…

Learn More

February 4, 2022

WATCH: FibroGen DMD Pamrevlumab Phase 3 Clinical Studies Highlight (Webinar Recording)

FibroGen joined PPMD for a webinar on February 2, 2022. During the webinar, FibroGen discussed the clinical rationale for the use of Pamrevlumab by highlighting its Phase 2 study in non-ambulatory participants with Duchenne and…

Learn More

July 6, 2021

Recently Reported Updates from PPMD’s 2021 Virtual Annual Conference

PPMD’s 2021 Virtual Annual Conference: Recently Reported Updates As a new addition to PPMD’s 2021 Virtual Conference, PPMD invited industry partners to share new data with the community live during the Conference in a series…

Learn More

August 11, 2020

FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial

FibroGen, Inc. announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with non-ambulatory Duchenne. PPMD is excited to see FibroGen’s continued…

Learn More

April 15, 2019

FibroGen Receives U.S. FDA Orphan Drug Designation for Pamrevlumab for the Treatment of Duchenne

FibroGen announced that FDA has granted Orphan Drug Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of people with Duchenne. According to their press release, all 21 non-ambulatory Duchenne patients in their ongoing…

Learn More

November 29, 2018

End Duchenne Tour Recap: Palo Alto, CA

PPMD headed to Palo Alto, CA for our End Duchenne Tour stop on November 3, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families….

Learn More